Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Diffusion Pharmaceuticals Inc. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
__________________
Date of Report (Date of earliest event reported): April 1, 2016
___________________
DIFFUSION PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
000-24477 |
30-0645032 |
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
|
2020 Avon Court, #4 Charlottesville, Virginia |
22902 |
|
(Address of principal executive offices) |
(Zip Code) |
(434) 220-0718
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
Item 5.02. |
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. |
Director Resignation
Effective as of April 1, 2016, Thomas Byrne resigned as member of the Board of Directors of Diffusion Pharmaceuticals Inc. (the “Company”). Mr. Byrne’s decision to resign was not due to any disagreement with the Company on any matter relating to its operations, policies or practices and Mr. Byrne. Mr. Byrne was appointed as the Company’s General Counsel effective as of April 1, 2016.
|
Item 8.01. |
Other Events. |
New Release
On April 1, 2016, the Company issued a news release announcing the resignation of Mr. Byrne and his appointment as the Company’s General Counsel. A copy of the news release is filed as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.
|
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits
|
Exhibit No. |
Description | ||
|
99.1 |
News Release issued by the Company on April 1, 2016 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Dated: April 1, 2016 |
DIFFUSION PHARMACEUTICALS INC. | ||||
|
|
|
|
| ||
|
|
|
|
| ||
|
|
By: |
/s/ David G. Kalergis |
| ||
| Name: | David G. Kalergis | ||||
| Title: | Chief Executive Officer | ||||
DIFFUSION PHARMACEUTICALS INC.
CURRENT REPORT ON FORM 8-K
EXHIBIT INDEX
|
Exhibit No. |
Description | |
|
99.1 |
News Release issued by the Company on April 1, 2016 |